Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections

Ryan K. Shields, Erin K. McCreary, Rachel V. Marini, Ellen G. Kline, Chelsea E. Jones, Binghua Hao, Liang Chen, Barry N. Kreiswirth, Yohei Doi, Cornelius J. Clancy, M. Hong Nguyen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

Original languageEnglish
Pages (from-to)667-671
Number of pages5
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume71
Issue number3
DOIs
Publication statusPublished - 27-07-2020

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections'. Together they form a unique fingerprint.

  • Cite this

    Shields, R. K., McCreary, E. K., Marini, R. V., Kline, E. G., Jones, C. E., Hao, B., Chen, L., Kreiswirth, B. N., Doi, Y., Clancy, C. J., & Nguyen, M. H. (2020). Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(3), 667-671. https://doi.org/10.1093/cid/ciz1131